AKT1 and nonpapillary renal cell carcinoma: Altogether, we showed that GSK690693, a pan-Akt inhibitor targeting Akt1/2/3, conferred selective inhibition in ccRCC cells with the PTEN mutation, which made it a potential individualized compound for such ccRCC patients.